Share Name Share Symbol Market Type Share ISIN Share Description
Hvivo LSE:HVO London Ordinary Share GB00B6ZM0X53 ORD 5P
  Price Change % Change Share Price Shares Traded Last Trade
  -2.50p -7.81% 29.50p 65,721 09:29:54
Bid Price Offer Price High Price Low Price Open Price
29.00p 30.00p 32.00p 29.50p 32.00p
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Health Care Equipment & Services 10.88 -14.82 -16.50 23.8

Hvivo (HVO) Latest News

More Hvivo News
Hvivo Takeover Rumours

Hvivo (HVO) Share Charts

1 Year Hvivo Chart

1 Year Hvivo Chart

1 Month Hvivo Chart

1 Month Hvivo Chart

Intraday Hvivo Chart

Intraday Hvivo Chart

Hvivo (HVO) Discussions and Chat

Hvivo Forums and Chat

Date Time Title Posts
16/11/201812:33hVIVO plc2,144

Add a New Thread

Hvivo (HVO) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
13:41:4029.654,7211,399.77O
10:31:4029.9010,0002,990.00O
09:38:1629.9015,0004,485.00O
09:33:2030.5032,0009,760.00O
09:28:5130.001,500450.00O
View all Hvivo trades in real-time

Hvivo (HVO) Top Chat Posts

DateSubject
16/11/2018
08:20
Hvivo Daily Update: Hvivo is listed in the Health Care Equipment & Services sector of the London Stock Exchange with ticker HVO. The last closing price for Hvivo was 32p.
Hvivo has a 4 week average price of 29.50p and a 12 week average price of 29.50p.
The 1 year high share price is 109p while the 1 year low share price is currently 15.50p.
There are currently 80,575,074 shares in issue and the average daily traded volume is 52,769 shares. The market capitalisation of Hvivo is £23,769,646.83.
13/11/2018
10:40
bernymadoff: The majority of people form opinions not based on company assets, financials and fundamentals but purely on the direction of the share price. They actually believe the Share Price is accurate/correct and true on a day-to-day basis regardless of the external factors that may affect it such as shorting, forced sellers etc. The biggest gains I have had on AIM by far have been my conviction buys that I've held for many months and sometimes well over a year. I have no doubt this will be right up there with the best of them.
06/11/2018
16:22
macangts: Berny I think the best way to respond to Samu would be to relent from further posting on HVO Let the share price do the talking. I think further chat from you will vindicate Samu analysis that you are a paid romper and doing the share no good service. Hold back man let everyone do there own analysis.
26/9/2018
07:51
tonyw99: I'm not saying either way but it doesn't matter when the options are exercised. They can be exercised (and then held) at any point for 8p and sold whenever she wants / needs cash. They wouldn't have "been allowed / advised" to cash them in at 160p - 210p because of the message it would give to the market - we're cashing out because we don't see any more upside. They could well be lining up a big payday however.....I'm not sure why the share price would spike on the back of it. If they sell as expected then they'll need the cash to run the service business. So unless they are going to return it to shareholders, that could be the only big gain. At which point, max capacity on revenue is c. £40m and a 10% return on ebitda would give off £4m. It wouldn't warrant a share price of more then £1 on 20 times PE
19/9/2018
09:49
discojames: a1samu if youre going to deramp at least put ome effort in to it. "The share price will continue to collapse on lack of news", thats a blatant false premise as the share price hasnt collapsed and in fact has barely moved in over 2 months.
19/9/2018
07:44
a1samu: The Directors have nothing concrete to report in the form of hard facts. There will be a lot of hot air of the future and potential and likely deals with unnamed parties, which will evaporate and the share price will continue to collapse on lack of news. They already released an RNS to say that news is imminent and we are still waiting. If there would be substantial news, like 10x bag value increase, they would not be able to hold it for the interim publication. Any substantial news they would be duty bound by the stock exchange rules to release immediately. As is, expect mediocre rubbish news tomorrow and further share price weakness, after perhaps a bounce, if lucky!
30/8/2018
07:53
discojames: I disagree, Berny. Any test, with any sample size has the possibility to be flawed. Getting parallel results from an independent body is actually important to verify them and the next step up in the share price. Every party involved (us included) will be very happy to hear that a third party has backed up the incredible results so far, and I can see it having a large affect on the share price. Any major in talks with HVO over Flu-V will be waiting on this verification, why would they sign a deal now when they are so close to reading the NIH findings, unless such a deal included a get-out clauses if NIH results don't back up those of HVO's. It will then just be a question of when rather than if a deal will be signed to move Flu-V to the next stage. I would prefer a takeover or a sale of the rights over a joint venture (I think HVO are targetting the latter), but any of these options work for us obviously, in terms of the share price
13/7/2018
22:48
applegarthlse: Not the first time shorters have gone after Neil Woodford? Read this article......Woodford slates Kerrisdale for shorting ProthenaFeature29 JAN 2018Neil Woodford hasn't held back in his criticism of the US hedge fund, Kerrisdale Capital, which recently moved to short one of his fund's top holdings, Prothena (PRTA.O).COMMENTWoodford Ingrid SmithIrish biotech company Prothena forms a relatively significant chunk of the Woodford Patient Capital Trust (WPCT).In November 2017 Kerrisdale published a less than positive 29-page report on Prothena, explaining why it had chosen to short the company's shares to inevitably profit from a fall in the share price, which saw a fall of nearly 28 per cent in Dollar terms on the Nasdaq.SPONSORED CONTENT Kubernetes on Windows – are we crazy?Kubernetes on Windows – are we crazy?By G-ResearchThe drop in Prothena's share price has cost it its top spot in the Patient Capital portfolio. From being the biggest holding at over 16 per cent of assets in October, it dropped to number two at 9.2 per cent by December, behind Oxford Nanopore, an unlisted university seeking to revolutionise DNA analysis.In its report, Kerrisdale argued that trials on Prothena's main drug under development – an antibody used to treat a rare disease called amyloidosis – is likely to fail and predicted Prothena will be 'the next big biotech blowup'.Woodford for his part said he is confident that Prothena, whose shares have rallied 20 per cent since the beginning of the New Year, will publish successful trial results in the second quarter, and forecasts there will be good news from other investments.'The next 6-12 months should see some important inflexion points, Woodford said. He added, "We are very confident about the portfolio", and said many companies in the Woodford Patient Capital Trust are "on the cusp" of a breakthrough.Some market watchers see Kerrisdale's comments as just another example of the long running feud between the hedge fund's founder, Sahm Adrangi, and Woodford.It was less than three years ago that Kerrisdale forecast shares in Allied Minds – a technology venture capitalist and another of the fund manager's long-term holdings – would tumble, describing many of its investments as 'duds'.Woodford has said Kerrisdale's raison d'etre is to frighten the market at a time when the market welcomes being frightened."It doesn't matter if what they said about Allied Minds and Prothena is totally inaccurate and unsubstantiated," Woodford told investors recently at a Winterflood Securities event in London.The star fund manager also argues that the financial press has a lot to answer for, by giving Kerrisdale "the oxygen of publicity" in order to achieve the self-fulfilled prophecy of a share price fall.The last year for Neil Woodford could be viewed as his very own annus horribilis, with all three of his funds having experienced a downturn in performance as key holdings have struggled – including the Woodford Equity Income fund which also invests in Prothena.And Woodford Patient Capital, which is an investment trust focused on early stage healthcare and technology companies, has certainly fared the worst.Since its inception in 2015 the fund's shares have fallen over 17 per cent to 83.4p, having lost 7 per cent of their value in 2017 and 9.75 per cent in 2016. This contrasts to August 2015, when they they were reported to show a 15 per cent premium over net asset value (NAV), but now trade at an 8.7 per cent discount to NAV.However, falls in the value of the underlying portfolio of 81 companies have been smaller, and the trust has still been able to report successes amongst it portfolio holdings – mostly notably from online estate agent Purplebricks(PURP), whose shares significantly jumped 194 per cent in 2017, according to Woodford Investment Management.
10/7/2018
18:41
snakesbelly: Found this article about Woodford and must admit makes me worried about his judgements ? Just hope he's called this one right ? .......................Few UK investors would have heard of Kerrisdale Capital three years ago, but after two high-profile victories against Neil Woodford, the small New York-based hedge fund is getting a name for itself on these shores.The collapse in the shares of Prothena (PRTA.O) this week after the failure of its flagship drug has richly rewarded Kerrisdale, which was 'shorting', or betting against, the stock, and punished Woodford, the biotech company's biggest investor. Kerrisdale labelled Prothena 'the next big biotech blow-up' in November as it announced its short on the stock, claiming the shares could fall as much as 80% and saying it was 'certain' of the failure of NEOD001, a potential therapy for AL Amyloidosis, a rare disease caused by the build-up of amyloid proteins.Less than six months later, Kerrisdale has been vindicated. Prothena has ceased further research into the drug after the failure of the phase 2b Pronto study into the treatment. The shares are down 82% since Kerrisdale started shorting them.It's the second time Kerrisdale, a small hedge fund operation running around $150 million (£108 million) in assets, has taken on Woodford, who ran £17.8 billion at the last count.In 2015, Kerrisdale launched a short-selling attack on long-term Woodford holding Allied Minds (ALML), branding the company, which commercialises intellectual property from universities, 'a dressed up collection of high-risk, low-reward gambles' and saying the shares could fall by 'at least' 70%. Three years on, the shares are down 78%.Both episodes have delivered major blows to Woodford's funds. Allied Minds was a top 10 holding when Woodford launched his Woodford Patient Capital (WPCT) investment trust in 2015, and sat just outside the top 10 when he launched his Woodford Equity Income fund a year earlier.Over the three years to the end of March, no stock has weighed more heavily on the performance of his Woodford Equity Income fund than Allied Minds, in a period that has also feature heavy share price falls from holdings like Provident Financial (PFG), Capita (CPI) and AA (AAAA). Prothena's impact on the Woodford Patient Capital investment trust has been even more dramatic. Prothena was the trust's largest holding when Kerrisdale launched its attack, representing a huge 16.3% of the fund's assets, although that had fallen to 9.1% by the end of March. The stock's 69% collapse on Monday saw shares in Woodford's trust tumble by more than 10%.The Woodford Equity Income fund, which held a 3.1% stake at the end of last month, and the Income Focus fund, with a 1.8% holding, have also been dented.Prothena's fall is likely to sting all the more for Woodford given Kerrisdale was a beneficiary, following the war of words between the two.Woodford branded Kerrisdale's Allied Minds attack as 'opportunistic', going further after the hedge fund took aim at Prothena.'Their job is to scare the market when the market is prepared to be scared. It doesn't matter if what they said about Allied Minds and Prothena is totally inaccurate and unsubstantiated,' he said earlier this year.'What matters is Bloomberg and others giving them the oxygen of publicity and hey presto there is a self-fulfilled prophecy and the share price falls.'Kerrisdale had in turn gone on the attack against the UK's most famous fund manager, arguing in its 29-page report on Prothena that investors should be wary of Woodford's 'repeated large mistakes in the biotech sector'.On Twitter, Kerrisdale claimed Woodford would 'lose money on your bad investments regardless of whether we write on them. But hopefully our work helps the widows and orphans who invest in your Patient Capital trust recognise how poor your diligence is on the stocks you pick'.
10/7/2018
13:55
bernymadoff: Leas, if you listen to all the interviews after the first set of results it is clear that the company have a lot of interest from big pharma for their flu vaccine and that the P2 results will be the catalyst for negotiations on a licensing deal. We are now on the cusp of receiving the final definitive P2 results after which according to the Executive Chairman they are looking to conclude a deal in the "very near future". With any smallcap AIM medical research company the risk is always that the trials don't go well. With HVO the overwhelming success of P2, and the fact that it has made clear it is seeking a partner for P3, means that the company is now largely derisked, certainly at this share price. There is a reason that institutions were buying in here at above £2 before the P2 trials and why they are loading up now and that is because they know the value that a universal flu vaccine can unlock. So from a short and medium term point of view it is a no brainer for me. Hold for the definitive results and watch the share price rise to at least £3 or a £200m market cap on successful conclusion of a deal with a major pharma this year.
06/7/2018
06:33
bernymadoff: IP are selling a few into a rising share price. That sale was made on Tuesday. We know that at the same time they've been selling Woodford has been buying. Actually Woodford is buying much more aggressively than they have been selling. Hence the share price has continued to rise. The rising share price tells us all we need to know which way the balance is tilted here
Hvivo share price data is direct from the London Stock Exchange
add chat code
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:40 V: D:20181116 13:58:53